CK-0804 is under clinical development by Cellenkos and currently in Phase I for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase I drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CK-0804’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CK-0804 overview
CK-0804 is under development for the treatment of primary myelofibrosis, myelofibrosis arising from polycythemia vera and essential thrombocythemia. It is administered by intravenous route and comprises of allogeneic cell therapy consisting of T-regulatory cells that exploit the CXCR4/CXCL12 axis and are derived from umbilical cord blood units.
Cellenkos overview
Cellenkos is an early-stage clinical biotechnology company, which focuses on the development of umbilical cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory disorders. The infusion of its lead product candidate, CK0801, leads to the replacement of defective T-REGs and protection of the body from T cell attacks with restoration of immune homeostasis. Cellenkos works in collaboration with the University of Texas MD Anderson Cancer Center to treat a wide range of autoimmune diseases including multiple sclerosis, lupus, rheumatoid arthritis and inflammatory disorders such as Crohn’s disease and aplastic anemia. The company is funded by Golden Meditech Holdings Limited to expand the T-REG technologies. Cellenkos is headquartered in Houston, Texas, the US.
For a complete picture of CK-0804’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Smarter leaders trust GlobalData
Premium Insights Likelihood of Approval and Phase Transition Success Rate Model - CK-0804 in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
Premium Insights
The gold standard of business intelligence.
